Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-08-09
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 20340000 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the health companies. LIS has previously announced and held an open tender contest for rare diseases (LIS 2199g). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
A contract was not signed for the active ingredient (Parathyrodeahormon, ATC code H05AA03, Natpar inj subst 50mcg/dose, 2x700mcg). Therefore there is still a need to enter into a new contract.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for rare diseases (LIS 2199g). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
A contract was not signed for the active ingredient (Parathyrodeahormon, ATC code H05AA03, Natpar inj subst 50mcg/dose, 2x700mcg). Therefore there is still a need to enter into a new contract.
Due to this lack of Natpar 100mcg/dose, LIS intends to enter into contracts between the regional health companies (the Contracting Authorities) and Takeda AS (the Supplier) as an supplementary contract to LIS 2199g, i.e., the scope and length of the contract must follow the mentioned procurement, subject to termination when the delivery situation is normalised, without a new competition being held for this ingredient. The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has explored the market situation and is of the opinion that it is not possible to hold a new competition or that a  supplier other than Takeda AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS [the Pharmaceutical Division] therefore believes that there are grounds to make the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this intention are submitted before the expiry of the waiting period, set to 13.08.2022. If no objections are received, contracts will be signed after the waiting period has expired.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) has explored the market situation and is of the opinion that it is not possible to hold a new contest or that a supplier other than Takeda AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. LIS [the Pharmaceutical Division] therefore believes that there are grounds to make the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.


Winner: Takeda AS
Award value: 20340000